top of page
AdobeStock_305758329_edited_edited.jpg

REDUCING prostate CANCER disparities IN SAN FRANCISCO

SF CAN aims to combat prostate cancer disparities through targeted early detection and follow-up of aggressive disease, and institutional partnerships that ensure high-quality treatment citywide. 

INFORMATION FOR CLINICIANS

page1.jpg
screening
page2.jpg
Skyline-Sunset%2011_edited.jpg

about prostate cancer

prostate-info_0.png

early detection & screening: The psa test

The primary test for prostate cancer, the PSA blood test, has been controversial and there are currently no guidelines to inform systematic testing.

 

The debate is due to the fact that all prostate cancers are not the same. Yet the PSA test cannot differentiate between “low-risk” disease that does not threaten life, and “high-risk” disease that is aggressive, will spread, and can be fatal.

 

Because the majority of prostate cancers are low-risk, past large-scale PSA testing in the general population led to extensive over-treatment of low-risk disease, often with debilitating side effects.

SFCAN_WebGraphic06tn.jpg
get screened
get involved
support

 

partner organizations

bottom of page